Potential new breathalyzer for lung cancer screening

Their work, described in a paper published this week in the journal Review of Scientific Instruments, from AIP Publishing, demonstrates the potential of the device to be used as a breathalyzer for early lung cancer detection — possibly a safe and effective method of detecting cancer early that may save lives. According to the researchers, the laboratory results are promising, but the device would still need to prove effective in clinical trials before its widespread adoption as a diagnostic tool. “Our results show that the device can discriminate different kinds and concentrations of cancer related volatile organic compounds with a nearly100 percent accurate rate,” said Jin-can Lei, the primary researcher and a postdoc from the College of Optoelectronic Engineering, Chongqing University. “This would also be a rapid method in that the entire detection process in our experiment only takes about 20 minutes.” Based on a small, circular plate called fluorescent cross-responsive sensor array, a specially-designed rotary gas chamber and a data collection and processing system, the device can detect lung cancer related gases at very low concentration, or below 50 parts per billion (ppb), showing a potential to identify lung cancer at the early stage. …

In lab research, team halts NASH liver damage

In a study published in Molecular Metabolism, Saint Louis University researchers have tested in an animal model a promising drug candidate that stopped fatty liver disease from progressing to the stage that causes severe liver damage. …

Cancer experience presents time for lifestyle changes in both survivors and family members

“A window of opportunity exists during the post-treatment transition period for oncology clinicians to reach out to patients and their caregivers who want to have a healthy start on life after cancer,” said Susan Mazanec, PhD, RN, AOCN, assistant professor at Case Western Reserve’s Frances Payne Bolton School of Nursing. Mazanec, also a nurse scientist at University Hospitals Case Medical Center’s Seidman Cancer Center, was lead investigator of the study, “Health Behaviors in Family Members of Patients Completing Cancer Treatment,” recently reported in Oncology Nursing Forum. Mazanec and colleagues surveyed and interviewed 50 patients diagnosed with breast, colorectal, head and neck, lung or prostate cancers and 38 caregivers within three week of a patient’s last treatment. The questions were designed to gauge family members’ intention, perceived benefit and confidence about eating a healthy diet, physical activity and smoking cessation…

3-D vaccine spontaneously assembles to pack a powerful punch against cancer, infectious diseases

“This vaccine is a wonderful example of applying biomaterials to new questions and issues in medicine,” says David Mooney, Ph.D., a professor of bioengineering at Harvard University in the School of Engineering and Applied Sciences, whose lab developed the vaccine. The project was co-led by Jaeyun Kim, Ph.D. and Aileen Li, a doctoral student in the Mooney lab. Their findings were published in the December 8, 2014 issue of Nature Biotechnology. …

Origins of colorectal cancer tumor cells traced

The scientists employed a “Big Bang” model of human colorectal cancer growth similar to the theory that the universe started from a single point and exploded outward. The team was led by Keck faculty researchers Darryl Shibata, M.D., professor of pathology, Keck School of Medicine of USC and Christina Curtis, Ph.D., M.Sc., assistant professor of medicine and genetics at Stanford University and adjunct assistant professor, department of Preventive Medicine, Keck School of Medicine of USC. “It’s like going back in time,” said Shibata. …

Cancer’s ability to ‘hijack’ regulatory mechanism increases metastasis

Scientists at The University of Texas MD Anderson Cancer Center and The University of North Carolina at Chapel Hill (UNC) have found that one component of this human scaffolding called collagen “cross-links” can determine a tumor’s ability to grow and spread. These cross-links of protein complexes enable connective tissue cells known as “stroma” to stiffen, stimulating tumor cell invasion and metastasis. Study results were published in today’s online edition of the Journal of Clinical Investigation…

Could there be a gleevec for brain cancer?

A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown. A team led by Antonio Iavarone, MD, professor of neurology and of pathology and cell biology, Institute for Cancer Genetics, previously discovered that a fusion of two proteins (present only in cancer cells and different from the two in CML) drives some cases of glioma, a common form of brain cancer. The team’s most recent study, published in Clinical Cancer Research, looked closely at two patients affected by recurrent glioblastoma with the fused proteins, in a first in-human trial of a drug that targets half of the fusion protein. Those patients, the researchers found, responded particularly well to the drug, with clinical improvement and radiological tumor reduction…